Stock Alert: Amyris (AMRS) Trades 11.77% Higher August 5

Equities Staff  |

Amyris Inc (NASDAQ:AMRS) shares gained 11.77% today on 7,234,888 shares - compared to the 30 day average of 5,446,325 shares traded.

As of today’s closing price of $1.90 the company has a 50 day moving average of $1.98.

The company is set to release earnings on 2022-08-09.

Amyris has moved 68.58% so far this year.

For technical charts, analysis, and more on Amyris visit the company profile.

About Amyris Inc

Amyris is a science and technology leader in the research, development and production of sustainable ingredients for the Clean Health & Beauty and Flavors & Fragrances markets. Amyris uses an impressive array of exclusive technologies, including state-of-the-art machine learning, robotics and artificial intelligence. Its ingredients are included in over 3,000 products from the world's top brands, reaching more than 200 million consumers. Amyris is proud to own three consumer brands - all built around its No Compromise® promise of clean ingredients: Biossance®clean beauty skincare, Pipette®clean baby skincare and Purecane™, a zero-calorie sweetener naturally derived from sugarcane.

To get more information on Amyris Inc and to follow the company's latest updates, you can visit the company's profile page here: Amyris Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

testforhref
The Strong Dollar Is a Problem for Stocks
3 Ways Finance Teams Can Navigate Inflation Through Automation



Market Movers

Sponsored Financial Content